GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
Fierce Biotech3d
GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
PharmExec2d
FDA Accepts Biologics License Application for GSK’s Depemokimab for Asthma with Type 2 Inflammation and CRSwNP
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
Medical Dialogues2d
USFDA accepts GSK depemokimab applications for review for asthma, chronic rhinosinusitis
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
FDA to review GSK's depemokimab
Pharmaceutical giant GSK said on Monday that the US Food and Drug Administration has agreed to review its Biologics License ...
EconoTimes3d
FDA Reviews GSK’s Depemokimab for Asthma and CRSwNP Treatment
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
Nasdaq3d
GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials
(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...
GlobalData on MSN3d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNP
Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
Investing.com Australia3d
US FDA accepts GSK’s application for Depemokimab review
Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...
MPR18h
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...